The about $50m raised at the mid-price would give the company an initial market capitalisation of about $239m on the Nasdaq stock exchange, according to its latest regulatory filing.
KaloBios Pharmaceuticals, a US-based developer of therapeutics for cancers and respiratory diseases backed by peer Baxter International, plans to sell 3.85 million shares at between $12 and $14 each in its flotation.
The about $50m raised at the mid-price would give the company an initial market capitalisation of about $239m on the Nasdaq stock exchange, according to its latest regulatory filing.
Investment bank Leerink Swann is lead underwriter and has the right to sell 4.4 million shares including an…
